

---

---

**Hsing-Chen Tsai, M.D., Ph.D.**

Graduate Institute of Toxicology

College of Medicine

National Taiwan University

No.1 Jen Ai road, Section 1, Taipei 100, Taiwan

Phone No.: 02-2312-3456 ext. 288797

Fax No.: 02-23410217

E-mail: [htsai@ntu.edu.tw](mailto:htsai@ntu.edu.tw)

Web: <http://tsailab.cm.ntu.edu.tw>

---

---

**Education**

- |           |                                                                              |
|-----------|------------------------------------------------------------------------------|
| 1992-1999 | M.D., National Taiwan University, Taiwan                                     |
| 2002-2004 | M.S., Graduate Institute of Clinical Medicine, National Taiwan Univ., Taiwan |
| 2005-2011 | Ph.D., Johns Hopkins University School of Medicine, USA                      |

**Research and Professional Positions Held in Chronological Sequence**

- |              |                                                                                                                                       |
|--------------|---------------------------------------------------------------------------------------------------------------------------------------|
| 1999-2002    | Resident, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan                                        |
| 2002-2004    | Clinical Fellow, Division of Chest Medicine, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan     |
| 2003-2004    | Chief Resident, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan                                  |
| 2011-2014    | Research Fellow, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, USA                   |
| 2014-2022    | Assistant Professor<br>Graduate Institute of Toxicology, College of Medicine, National Taiwan University, Taipei, Taiwan              |
| 2014-present | Attending physician, Division of Chest Medicine, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan |
| 2021-present | Deputy Director, NTUH Center for Frontier Medicine, National Taiwan University Hospital, Taipei, Taiwan                               |
| 2022-present | Associate Professor<br>Graduate Institute of Toxicology, College of Medicine, National Taiwan University, Taipei, Taiwan              |
| 2025-present | Joint Appointment Associate Research Fellow, Institute of Biomedical Sciences, Academia Sinica                                        |

**Research Interests**

Our research focuses on unraveling the intricate interplay between cancer cells and the tumor immune microenvironment from an epigenetics perspective. By bridging basic

research, translational medicine, and clinical applications, our goal is to develop innovative cancer immunotherapies and diagnostic strategies, ultimately leading to improved patient outcomes.

*Our key research directions include:*

- Epigenetic Regulation of the Tumor Immune Microenvironment — We investigate how epigenetic mechanisms shape the tumor immune microenvironment by regulating immune cell differentiation, activation, and dysfunction. Using a targeted drug screening platform, we have identified epigenetic compounds that restore polyfunctionality and plasticity in exhausted T cells. Our research explores the metabolic pathways underlying these effects and their broader impact on anti-tumor immunity. We also apply multi-omics approaches to characterize peripheral immune alterations in early-stage lung cancer, aiming to identify blood-based epigenetic biomarkers and develop strategies to restore systemic immune competence.
- $\gamma\delta$  T Cell-Based Cancer Immunotherapy — Our lab develops  $\gamma\delta$  T cells for adoptive cellular immunotherapy, leveraging their HLA-independent tumor recognition and rapid cytotoxic activity. We have established a clinical-grade  $\gamma\delta$  T cell expansion protocol and are optimizing it for regulatory compliance. Concurrently, we study the molecular and synaptic mechanisms of  $\gamma\delta$  T cell-mediated tumor killing and are identifying predictive biomarkers of expansion efficiency and therapeutic potency. Our goal is to enable  $\gamma\delta$  T cell-based precision immunotherapies for clinical application.

### **Major Honors and Awards**

2005	Taiwan Merit Scholarship, by Taiwan's Ministry of Education, Council for Economic Planning and Development, and National Science Council
2012	Honorable Mention for Basic Research, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2016	Best oral presentation award, Annual Meeting of Pulmonary Critical Care Medicine, Taiwan Society of Pulmonary and Critical Care Medicine
2017	Young Investigator Outstanding Research Award, National Taiwan University Hospital (臺大醫院傑出研究獎)
2020	The ITRI 2020 Janssen-Taiwan Research Grant Awardee
2021	The 18 <sup>th</sup> National Innovation Award (國家新創獎)
2022	The Ming Chai Medical and Education Foundation Interdisciplinary Research Award
2024	Fellow of the Asian Pacific Society of Respiriology (亞太呼吸學會會士)